
## Jocelyn Qi-Min Teo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8382004/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 719421.	3.9	3
2	Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. MSphere, 2021, 6, .	2.9	29
3	Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study. International Journal of Antimicrobial Agents, 2021, 57, 106340.	2.5	14
4	Genomic characterization of carbapenem-non-susceptible <i>Pseudomonas aeruginosa</i> in Singapore. Emerging Microbes and Infections, 2021, 10, 1706-1716.	6.5	13
5	In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant Klebsiella pneumoniae With Different Carbapenemases and Sequence Types. Frontiers in Microbiology, 2021, 12, 779988.	3.5	5
6	Determining the Development of Persisters in Extensively Drug-Resistant Acinetobacter baumannii upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
7	Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study. Antibiotics, 2020, 9, 451.	3.7	14
8	Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria. Microorganisms, 2020, 8, 1489.	3.6	1
9	Human MAIT cell cytolytic effector proteins synergize to overcome carbapenem resistance in Escherichia coli. PLoS Biology, 2020, 18, e3000644.	5.6	37
10	<i>In Vitro</i> Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3
11	Title is missing!. , 2020, 18, e3000644.		0
12	Title is missing!. , 2020, 18, e3000644.		0
13	Title is missing!. , 2020, 18, e3000644.		Ο
14	Title is missing!. , 2020, 18, e3000644.		0
15	Title is missing!. , 2020, 18, e3000644.		0
16	Title is missing!. , 2020, 18, e3000644.		0
17	In vitro Pharmacodynamics and PK/PD in Animals. Advances in Experimental Medicine and Biology, 2019, 1145, 105-116.	1.6	7
18	Candida auris in Singapore: Genomic epidemiology, antifungal drug resistance, and identification using the updated 8.01 VITEKⓇ2 system. International Journal of Antimicrobial Agents, 2019, 54, 709-715.	2.5	17

Jocelyn Qi-Min Teo

#	Article	IF	CITATIONS
19	Molecular mechanisms of azole resistance in Candida bloodstream isolates. BMC Infectious Diseases, 2019, 19, 63.	2.9	34
20	Do antimicrobial stewardship programme interventions reduce the rate of and protect against Clostridium difficile infection?. Journal of Global Antimicrobial Resistance, 2019, 17, 312-315.	2.2	1
21	Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case–control study. International Journal of Antimicrobial Agents, 2019, 53, 657-662.	2.5	13
22	708. Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients. Open Forum Infectious Diseases, 2018, 5, S255-S255.	0.9	0
23	Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2018, 76, 48-57.	3.3	16
24	Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. Infection and Drug Resistance, 2018, Volume 11, 1591-1596.	2.7	6
25	Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	10
26	Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes. Antimicrobial Resistance and Infection Control, 2017, 6, 27.	4.1	24
27	Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
28	Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. Microorganisms, 2016, 4, 13.	3.6	26
29	From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB). PLoS ONE, 2016, 11, e0158740.	2.5	13
30	Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients. Annals of Pharmacotherapy, 2016, 50, 790-792.	1.9	5
31	Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 4013-4022.	3.2	24
32	mcr-1in Multidrug-ResistantblaKPC-2-Producing Clinical Enterobacteriaceae Isolates in Singapore. Antimicrobial Agents and Chemotherapy, 2016, 60, 6435-6437.	3.2	29
33	<i>In Vitro</i> Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Antimicrobial Agents and Chemotherapy, 2016, 60, 5238-5246.	3.2	14
34	Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours. PLoS ONE, 2015, 10, e0140446.	2.5	10
35	Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution. BMC Infectious Diseases, 2015, 15, 256.	2.9	7
36	Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae. Journal of Infection, 2015, 70, 309-311.	3.3	20

Jocelyn Qi-Min Teo

#	Article	IF	CITATIONS
37	<i>In Vitro</i> Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 2515-2524.	3.2	39
38	Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrobial Resistance and Infection Control, 2015, 4, 2.	4.1	42
39	Multiple Genetic Mutations Associated with Polymyxin Resistance in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2015, 59, 7899-7902.	3.2	35
40	Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis. International Journal of Antimicrobial Agents, 2014, 43, 403-411.	2.5	77
41	ST22 and ST239 MRSA duopoly in Singaporean hospitals: 2006–2010. Epidemiology and Infection, 2013, 141, 153-157.	2.1	22
42	Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 3041-3046.	2.9	19
43	Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. International Journal of Antimicrobial Agents, 2012, 40, 55-60.	2.5	46
44	Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study. PLoS ONE, 2012, 7, e34254.	2.5	38
45	The effect of a whole-system approach in an antimicrobial stewardship programme at the Singapore General Hospital. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 947-955.	2.9	29
46	Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B. PLoS ONE, 2011, 6, e28177.	2.5	51